Print Page      Close Window     

Investor Relations Home

Accuray Incorporated is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The Company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.

Accuray does not assume a duty to update information on this website, except through the normal quarterly financial press releases and regulatory filings.

ARAY (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.15 (3.75%)
Data as of May 26, 2017 4:00 p.m. ET
Refresh quote
Stock chart for: ARAY.O.  Currently trading at $4.15 with a 52 week high of $6.39 and a 52 week low of $3.85.
Data provided by Nasdaq. Minimum 15 minutes delayed.

Press Releases

Accuray Appoints Stan Gee VP of Revenue Management
SUNNYVALE, Calif., May 24, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today it has appointed, Stan Gee, who has been with Accuray for over eight years, to the newly created Vice President of Revenue Management position reporti... 
May 24, 2017
New Data Reinforce Benefits of TomoTherapy® Platform for Mainstream Radiation Therapy Treatment Indications
Multiple Studies Presented at ESTRO 36 Demonstrate System Improves Tumor Control withReduced Toxicities SUNNYVALE, Calif., May 11, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that studies continue to demonstrate the ... 
May 11, 2017

Upcoming Investor Event

There are currently no events scheduled.
Some documents in the Investor Relations section require that you have Adobe Acrobat Reader® installed in order to view files in PDF format. Download the newest version of Acrobat Reader